The GI industry hit a milestone in May with the first FDA approved treatment for eosinophilic esophagitis.
The treatment, Dupixent, was approved to treat eosinophilic esophagitis in adults and pediatric patients 12 and older weighing at least 88 pounds.
Marc Rothenberg, MD, PhD, director of the Cincinnati Center for Eosinophilic Diseases at Cincinnati Children’s, spoke with Becker’s on June 8 to discuss the approval of the first eosinophilic esophagitis treatment, its significance and the challenges that came with researching the disease.